Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors

Karin Schreiber, Ronald E. Cannon, Theodore Karrison, Gabriele Beck-Engeser, Dezheng Huo, Raymond W. Tennant, Heather Jensen, W. Martin Kast, Thomas Krausz, Stephen C. Meredith, Lieping Chen, Hans Schreiber

Research output: Contribution to journalArticle

Abstract

E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the development of certain types of cancers. However, these oncogenes are insufficient to transform normal cells into an immortalized or malignant state. Mutant Ha-ras cooperates with E6/E7 of HPV subtype 16 in transformation of cells in vitro and may contribute to some HPV-associated cancers in humans. This study investigates whether HPV16 E6/E7 and v-Ha-ras synergize in vivo. FVB/n mice transgenic for V-Ha-ras gene (R+) were crossed with transgenic C57BL/ 6 mice that harbor E6/E7 of HPV16 (E +). Beginning at about 3 months of age, the bitransgenic E +R+(C57BL/ 6 x FVB/n) F1 mice developed mouth, eye and ear tumors. By 6 months, the prevalence of these types of mouth, eye and ear tumors was 100, 71 and 79% respectively in the E+R+ mice. Most tumors grew progressively until the mice had to be killed. The median times for the appearance of the first mouth, eye and ear tumor were 3.6, 4.3 and 4.2 months, respectively. For the two singly transgenic groups of mice, the prevalence of mouth, eye and ear tumors was 0, 0 and 6% (E-R +) and 0, 0 and 0% (E+R-), respectively, and the median time to first tumor was greater than 12 months for singly transgenic mice (E-R+, E+R-). Thus, a remarkable synergy occurred between the v-Ha-ras and HPV16 E6/E7 oncogenes in the development of primary tumors in mice.

Original languageEnglish (US)
Pages (from-to)3972-3979
Number of pages8
JournalOncogene
Volume23
Issue number22
DOIs
StatePublished - May 13 2004
Externally publishedYes

Fingerprint

Papillomaviridae
Neoplasms
Transgenic Mice
Ear
Mouth
Oncogenes
ras Genes
Inbred C57BL Mouse

Keywords

  • E6/E7
  • HPV 16
  • Human papilloma virus 16
  • Primary tumors
  • Synergy
  • Transgenic mice
  • vHa ras

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Schreiber, K., Cannon, R. E., Karrison, T., Beck-Engeser, G., Huo, D., Tennant, R. W., ... Schreiber, H. (2004). Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene, 23(22), 3972-3979. https://doi.org/10.1038/sj.onc.1207507

Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. / Schreiber, Karin; Cannon, Ronald E.; Karrison, Theodore; Beck-Engeser, Gabriele; Huo, Dezheng; Tennant, Raymond W.; Jensen, Heather; Kast, W. Martin; Krausz, Thomas; Meredith, Stephen C.; Chen, Lieping; Schreiber, Hans.

In: Oncogene, Vol. 23, No. 22, 13.05.2004, p. 3972-3979.

Research output: Contribution to journalArticle

Schreiber, K, Cannon, RE, Karrison, T, Beck-Engeser, G, Huo, D, Tennant, RW, Jensen, H, Kast, WM, Krausz, T, Meredith, SC, Chen, L & Schreiber, H 2004, 'Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors', Oncogene, vol. 23, no. 22, pp. 3972-3979. https://doi.org/10.1038/sj.onc.1207507
Schreiber K, Cannon RE, Karrison T, Beck-Engeser G, Huo D, Tennant RW et al. Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004 May 13;23(22):3972-3979. https://doi.org/10.1038/sj.onc.1207507
Schreiber, Karin ; Cannon, Ronald E. ; Karrison, Theodore ; Beck-Engeser, Gabriele ; Huo, Dezheng ; Tennant, Raymond W. ; Jensen, Heather ; Kast, W. Martin ; Krausz, Thomas ; Meredith, Stephen C. ; Chen, Lieping ; Schreiber, Hans. / Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. In: Oncogene. 2004 ; Vol. 23, No. 22. pp. 3972-3979.
@article{090926bfb3574c4795c6ce9d2cfa36d6,
title = "Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors",
abstract = "E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the development of certain types of cancers. However, these oncogenes are insufficient to transform normal cells into an immortalized or malignant state. Mutant Ha-ras cooperates with E6/E7 of HPV subtype 16 in transformation of cells in vitro and may contribute to some HPV-associated cancers in humans. This study investigates whether HPV16 E6/E7 and v-Ha-ras synergize in vivo. FVB/n mice transgenic for V-Ha-ras gene (R+) were crossed with transgenic C57BL/ 6 mice that harbor E6/E7 of HPV16 (E +). Beginning at about 3 months of age, the bitransgenic E +R+(C57BL/ 6 x FVB/n) F1 mice developed mouth, eye and ear tumors. By 6 months, the prevalence of these types of mouth, eye and ear tumors was 100, 71 and 79{\%} respectively in the E+R+ mice. Most tumors grew progressively until the mice had to be killed. The median times for the appearance of the first mouth, eye and ear tumor were 3.6, 4.3 and 4.2 months, respectively. For the two singly transgenic groups of mice, the prevalence of mouth, eye and ear tumors was 0, 0 and 6{\%} (E-R +) and 0, 0 and 0{\%} (E+R-), respectively, and the median time to first tumor was greater than 12 months for singly transgenic mice (E-R+, E+R-). Thus, a remarkable synergy occurred between the v-Ha-ras and HPV16 E6/E7 oncogenes in the development of primary tumors in mice.",
keywords = "E6/E7, HPV 16, Human papilloma virus 16, Primary tumors, Synergy, Transgenic mice, vHa ras",
author = "Karin Schreiber and Cannon, {Ronald E.} and Theodore Karrison and Gabriele Beck-Engeser and Dezheng Huo and Tennant, {Raymond W.} and Heather Jensen and Kast, {W. Martin} and Thomas Krausz and Meredith, {Stephen C.} and Lieping Chen and Hans Schreiber",
year = "2004",
month = "5",
day = "13",
doi = "10.1038/sj.onc.1207507",
language = "English (US)",
volume = "23",
pages = "3972--3979",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "22",

}

TY - JOUR

T1 - Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors

AU - Schreiber, Karin

AU - Cannon, Ronald E.

AU - Karrison, Theodore

AU - Beck-Engeser, Gabriele

AU - Huo, Dezheng

AU - Tennant, Raymond W.

AU - Jensen, Heather

AU - Kast, W. Martin

AU - Krausz, Thomas

AU - Meredith, Stephen C.

AU - Chen, Lieping

AU - Schreiber, Hans

PY - 2004/5/13

Y1 - 2004/5/13

N2 - E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the development of certain types of cancers. However, these oncogenes are insufficient to transform normal cells into an immortalized or malignant state. Mutant Ha-ras cooperates with E6/E7 of HPV subtype 16 in transformation of cells in vitro and may contribute to some HPV-associated cancers in humans. This study investigates whether HPV16 E6/E7 and v-Ha-ras synergize in vivo. FVB/n mice transgenic for V-Ha-ras gene (R+) were crossed with transgenic C57BL/ 6 mice that harbor E6/E7 of HPV16 (E +). Beginning at about 3 months of age, the bitransgenic E +R+(C57BL/ 6 x FVB/n) F1 mice developed mouth, eye and ear tumors. By 6 months, the prevalence of these types of mouth, eye and ear tumors was 100, 71 and 79% respectively in the E+R+ mice. Most tumors grew progressively until the mice had to be killed. The median times for the appearance of the first mouth, eye and ear tumor were 3.6, 4.3 and 4.2 months, respectively. For the two singly transgenic groups of mice, the prevalence of mouth, eye and ear tumors was 0, 0 and 6% (E-R +) and 0, 0 and 0% (E+R-), respectively, and the median time to first tumor was greater than 12 months for singly transgenic mice (E-R+, E+R-). Thus, a remarkable synergy occurred between the v-Ha-ras and HPV16 E6/E7 oncogenes in the development of primary tumors in mice.

AB - E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the development of certain types of cancers. However, these oncogenes are insufficient to transform normal cells into an immortalized or malignant state. Mutant Ha-ras cooperates with E6/E7 of HPV subtype 16 in transformation of cells in vitro and may contribute to some HPV-associated cancers in humans. This study investigates whether HPV16 E6/E7 and v-Ha-ras synergize in vivo. FVB/n mice transgenic for V-Ha-ras gene (R+) were crossed with transgenic C57BL/ 6 mice that harbor E6/E7 of HPV16 (E +). Beginning at about 3 months of age, the bitransgenic E +R+(C57BL/ 6 x FVB/n) F1 mice developed mouth, eye and ear tumors. By 6 months, the prevalence of these types of mouth, eye and ear tumors was 100, 71 and 79% respectively in the E+R+ mice. Most tumors grew progressively until the mice had to be killed. The median times for the appearance of the first mouth, eye and ear tumor were 3.6, 4.3 and 4.2 months, respectively. For the two singly transgenic groups of mice, the prevalence of mouth, eye and ear tumors was 0, 0 and 6% (E-R +) and 0, 0 and 0% (E+R-), respectively, and the median time to first tumor was greater than 12 months for singly transgenic mice (E-R+, E+R-). Thus, a remarkable synergy occurred between the v-Ha-ras and HPV16 E6/E7 oncogenes in the development of primary tumors in mice.

KW - E6/E7

KW - HPV 16

KW - Human papilloma virus 16

KW - Primary tumors

KW - Synergy

KW - Transgenic mice

KW - vHa ras

UR - http://www.scopus.com/inward/record.url?scp=2542583106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542583106&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1207507

DO - 10.1038/sj.onc.1207507

M3 - Article

C2 - 15077191

AN - SCOPUS:2542583106

VL - 23

SP - 3972

EP - 3979

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 22

ER -